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Introduction {#jdv14973-sec-0006}
============

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by pruritic erythematous scaly lesions and dryness of the skin. The majority of patients with AD are treated in an outpatient setting, where the mainstay of therapy is focused on basic skin care with moisturizers and topical treatments with steroids and immunosuppressants. However, in some cases, patients with AD are refractory to these conventional treatments, making it a difficult‐to‐treat disease. Several authors have reviewed the subject of difficult‐to‐treat or difficult‐to‐control AD, stating diverse possible explanations for the problem, such as lack of compliance,[1](#jdv14973-bib-0001){ref-type="ref"} psychosocial factors,[2](#jdv14973-bib-0002){ref-type="ref"}, [3](#jdv14973-bib-0003){ref-type="ref"} skin infections,[4](#jdv14973-bib-0004){ref-type="ref"}, [5](#jdv14973-bib-0005){ref-type="ref"} exacerbations triggered by food and aeroallergens,[6](#jdv14973-bib-0006){ref-type="ref"}, [7](#jdv14973-bib-0007){ref-type="ref"}, [8](#jdv14973-bib-0008){ref-type="ref"} and concomitant allergic contact dermatitis (ACD).[9](#jdv14973-bib-0009){ref-type="ref"}, [10](#jdv14973-bib-0010){ref-type="ref"}, [11](#jdv14973-bib-0011){ref-type="ref"} All these factors may contribute to making the disease difficult‐to‐treat.

Historically, patients with AD were thought to be less prone to develop ACD, because of a decreased cell‐mediated immunity.[12](#jdv14973-bib-0012){ref-type="ref"}, [13](#jdv14973-bib-0013){ref-type="ref"} Recent studies, however, show that atopic individuals are at least as likely to develop ACD compared to non‐atopic individuals.[14](#jdv14973-bib-0014){ref-type="ref"}, [15](#jdv14973-bib-0015){ref-type="ref"}, [16](#jdv14973-bib-0016){ref-type="ref"}, [17](#jdv14973-bib-0017){ref-type="ref"}, [18](#jdv14973-bib-0018){ref-type="ref"}, [19](#jdv14973-bib-0019){ref-type="ref"}, [20](#jdv14973-bib-0020){ref-type="ref"}, [21](#jdv14973-bib-0021){ref-type="ref"} Additionally, lack of functional filaggrin has been shown to increase the risk of ACD in patients with AD.[22](#jdv14973-bib-0022){ref-type="ref"}, [23](#jdv14973-bib-0023){ref-type="ref"}

As can be expected from frequent exposition to allergens in topical therapy, allergies to lanolin alcohols and antiseptics occur regularly within patients with AD.[21](#jdv14973-bib-0021){ref-type="ref"}, [24](#jdv14973-bib-0024){ref-type="ref"} Several specific allergic contact reactions are described to occur more often in AD children compared to healthy children. A large multicentre study in Dutch children showed that children with AD were significantly more often sensitized to fragrances and wool alcohols.[21](#jdv14973-bib-0021){ref-type="ref"} Also, potassium dichromate, disperse blue 106 and compositae mix are frequent sensitizers.[25](#jdv14973-bib-0025){ref-type="ref"} If corticosteroid therapy is not sufficient for treating AD anymore, many dermatologists may suspect an allergy for corticosteroids.[24](#jdv14973-bib-0024){ref-type="ref"}, [26](#jdv14973-bib-0026){ref-type="ref"}, [27](#jdv14973-bib-0027){ref-type="ref"}

We investigated the occurrence of a concomitant ACD in a population of difficult‐to‐treat AD patients, which had to be admitted to a specialized day care treatment unit for AD because of unresponsiveness to conventional outpatient treatments. This study aims to (i) determine the rate of ACD in this population of difficult‐to‐treat AD, (ii) identify the most common allergens and determine their allergic and irritative properties by dynamic patch test analysis and (iii) determine the rate of polysensitization in this population.

Materials and methods {#jdv14973-sec-0007}
=====================

Patients {#jdv14973-sec-0008}
--------

We performed a retrospective analysis of 190 patients with a clinical diagnosis of AD that had been seen between November 2012 and February 2015 at the Academic Medical Center (AMC) day care treatment centre because of difficult‐to‐treat AD. The UK Working Party criteria[28](#jdv14973-bib-0028){ref-type="ref"} were retrospectively applied to all patients. Forty‐eight patients were excluded because they did not meet diagnostic criteria. Of the 142 patients having the diagnosis of AD according to the UK Working Party criteria (UK+ patients), 69 patients (*n* = 69/142; 49%) were referred for patch testing because of suspected ACD, but 51 patients (*n* = 51/142; 36%) actually underwent patch testing. Only patch test series applied in at least 50% of tested patients were included for analysis. These were the European Baseline Series (EBS; *n* = 45/51; 88%), a routine supplementary series (*n* = 42/51; 82%), wool alcohol series (*n* = 40/51; 80%) and corticosteroid series (*n* = 35/51; 69%; Table [1](#jdv14973-tbl-0001){ref-type="table"}). Two UK+ patients (*n* = 2/51) were not tested with any of these series and were therefore excluded from further analysis. Additionally, one UK+ patient in which EBS was applied, had an angry back at time of the readings and was therefore not included in further analysis. This study will therefore discuss patch test results of 48 UK+ patients (48/142; 34%) tested with the abovementioned patch test series. In patients with full body pictures available, eczema area and severity index score (EASI) were determined in retrospect by two experienced observers.

###### 

Administered patch test panels to 51 UK+, difficult‐to‐treat atopic dermatitis patients

  Test series                                   *n* (%)
  --------------------------------------------- ----------
  European baseline series                      45 (88%)
  Corticosteroids, including the solvent DMSO   35 (69%)
  Epoxy resins                                  1 (2%)
  Essential oils                                3 (6%)
  External drugs                                5 (10%)
  Glues                                         1 (2%)
  Parabens                                      8 (16%)
  Beta‐lactams                                  1 (2%)
  Perfumes                                      3 (6%)
  Photo‐contact allergens                       1 (2%)
  Rubber accelerators                           4 (8%)
  Shoe ingredients                              4 (8%)
  Supplementary series                          42 (82%)
  Textile dyes                                  4 (8%)
  TRUE test                                     6 (12%)
  Titanium salts                                1 (2%)
  Wool alcohols                                 40 (80%)

UK+, meeting UK Working Party criteria.
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Patch tests {#jdv14973-sec-0009}
-----------

Patients were routinely tested with the EBS and a routine supplementary series unless contraindicated, and with additional patch test series depending on the patient\'s history and physical examination. Patch tests were performed with van der Bend square chambers (van der Bend, Brielle, The Netherlands) in combination with allergens from Almirall (Reinbek, Germany) or Chemotechnique (Vellinge, Sweden), or the TRUE Test^®^ (SmartPractice Denmark, Hillerød, Denmark). Readings were performed on day (D) 2 and D3. The reactions were scored according to the recommendations of the ICDRG and ESCD.[29](#jdv14973-bib-0029){ref-type="ref"} The clinical relevance was determined for each positive patch test result. Clinical relevance was scored as follows: 'definite' when the clinician was 100% convinced that the allergen was causative for the dermatitis, the patient was exposed to the allergen, the allergen was present in the environment of the patient, and sites of dermatitis had a clear relationship with the allergen‐containing product; 'probable' when there was a strong relationship between the allergen and dermatitis; 'possible' when the relationship between the allergen and dermatitis was less clear, but the allergen was nevertheless suspected to have cause ACD; and 'unlikely‐not/uncertain' when ACD was not suspected. Relevance scores provided in this article refer to 'definite' and 'probable' relevance scores, and of current relevance. This study was exempt from medical ethics committee approval.

Data analysis {#jdv14973-sec-0010}
-------------

To determine the prevalence of positive patch tests (PPT) to the allergens in the investigated series (EBS, routine supplementary series (Table [2](#jdv14973-tbl-0002){ref-type="table"}), wool alcohol series and corticosteroid series), we divided the positive reactions per allergen by the total number of times that the allergen was tested (PPT%).

###### 

Allergens of routine supplementary series

  -----------------------------------------
  Disperse blue 106
  Diazolidinyl urea
  1,2‐benzoisothiazolin‐3‐one sodium salt
  Imidazolidinyl urea
  Turpentine peroxide
  2‐bromo‐2‐nitropropane‐13‐diole
  Carbamix
  Ethylenediamine‐di‐HCl
  Thiomersal
  Amerchol L101
  p‐toluenesulfonamide
  Cocamidopropyl betaine
  Hydrocortisone‐17‐butyrate
  2‐*n*‐octyl‐4‐isothiazolin‐3‐on
  Iodopropynyl butylcarbamate
  Sorbitansesquioleate
  2‐phenoxyethanol
  Methylisothiazolinone
  Tixocortol pivalate
  Benzophenone‐4
  Sodium metabisulfite
  Propyl gallate
  Dimethylaminopropylamine
  -----------------------------------------
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To identify the allergens that were both the most common and the most relevant, we multiplied the prevalence with the relevance score of 'definite' and 'probable', current relevance, obtaining the percentage of clinically relevant patch tests (RPPT%).

As patch testing in patients with AD is challenging because of an increased risk of irritant patch test reactions, dynamic patch test analysis has also been performed.[30](#jdv14973-bib-0030){ref-type="ref"}, [31](#jdv14973-bib-0031){ref-type="ref"} Dynamic patch test analysis shows how a patch test reaction evolves over several days (from D2 to D3 readings), whereby crescendo and plateau reactions are considered to be truly allergic reactions, and decrescendo reactions are considered to be irritant reactions.

We also determined the amount of polysensitization present in this population of difficult‐to‐treat AD. Polysensitization was defined as an allergic reaction to three or more unrelated contact allergens.[32](#jdv14973-bib-0032){ref-type="ref"}, [33](#jdv14973-bib-0033){ref-type="ref"} Analysed allergens were grouped together according to cross‐reactivity, concomitant exposure, and releasers of similar compounds, as for example in formaldehyde releasers (Table [S1](#jdv14973-sup-0001){ref-type="supplementary-material"}). A patient was considered polysensitized in case the patient reacted to at least three different groups of allergens.

All statistical analyses were performed in SPSS^®^, software version 21.0 (SPSS, Inc., Chicago, IL, USA). Distribution was tested by Q--Q plot and Kolmogorov--Smirnov or Shapiro--Wilk test depending on sample size. Continuous variables are presented as mean (standard deviation) or median \[interquartile range (IQR)\] according to their distribution.

Results {#jdv14973-sec-0011}
=======

Rate of ACD in difficult‐to‐treat AD {#jdv14973-sec-0012}
------------------------------------

Of the 48 UK+ patients analysed, the median age was 14.6 years (IQR: 10.1--19.0), of which 71% were children (*n* = 34/48) and 29% were adults (*n* = 14/48), with 44% (*n* = 21/48) being male. Mean EASI score was 25 (IQR: 12--41; available in 26/48 patients). We found that 75% (*n* = 36/48) of patients had at least one positive patch test, of which 67% (*n* = 24/36) were children (age below 18 years) and 33% (*n* = 12/36) were adults. In these 36 patients, the median age \[median 15.2 years (IQR: 10.8--20.6; range: 4.2--54.6 years), *P* = 0.396\] and number of males (44%, *n* = 16, *P* = 0.563) did not differ from the 48 UK+ patients.

Most common allergens and relevance {#jdv14973-sec-0013}
-----------------------------------

Table [3](#jdv14973-tbl-0003){ref-type="table"} shows PPT% en RPPT% of the most common sensitizers in the total population, as well as for children and adults separately. The ten most frequent allergens in the total population were bichromate (*n* = 12/44, PPT 27%) and nickel (*n* = 12/44, PPT 27%), wool alcohols (*n* = 10/41, PPT 24%), cocamidopropyl betaine (CAPB; *n* = 10/44, PPT 24%), amerchol L101 (*n* = 11/47, PPT 23%), wollwachsalkoholsalbe DAB9 (German wool wax emollient, containing 75% wool wax and 25% water; *n* = 10/44, PPT 23%), cremor lanette (*n* = 7/40, PPT 18%), dimethylaminopropylamine (DMAPA)(*n* = 7/42, PPT 17%), cobalt (*n* = 5/44, PPT 11%) and eucerine cum aqua (*n* = 4/40, PPT 10%). Relevance scores (current 'definite' and 'probable' relevance) were 100% for all allergens except for bichromate (43%), nickel(II)‐sulphate (13%) and cobalt (33%).

###### 

Most common positive patch test results in 48 UK+ difficult‐to‐treat atopic dermatitis patients: Top 10 allergens and additional allergens according to relevant positive patch tests

                                                                          Total group (*n* = 48)   Children (0--17 years) (*n* = 34)   Adults (18+ years) (*n* = 14)                                                                                                                                                                                                               
  ----------------------------------------------------------------------- ------------------------ ----------------------------------- ------------------------------- ------------- -------- ----------------------------------------------------------------------- ---- --------- ---- -------------------------------------------------------------------------- ---- -------- ----
  1\) Bichromate                                                          44                       27 (12)                             12                              14 (10--17)   42 (5)   1\) Amerchol L101                                                       30   37 (11)   37   1\) Nickel(II)‐sulphate                                                    14   29 (4)   0
  2\) Nickel(II)‐sulphate                                                 44                       27 (12)                             3                               15 (10--22)   67 (8)   2\) Bichromate                                                          30   33 (10)   14   2\) Cocamidopropyl betaine                                                 14   21 (3)   21
  3\) Wool alcohols                                                       41                       24 (10)                             24                              14 (10--16)   30 (3)   3\) Wool alcohols                                                       30   30 (9)    30   3--12) Bichromate                                                          14   14 (2)   14
  4\) Cocamidopropyl betaine                                              42                       24 (10)                             24                              16 (12--25)   50 (5)   4\) Nickel(II)‐sulphate                                                 30   27 (8)    5    3--12) Caine‐mix III[b](#jdv14973-note-0004){ref-type="fn"}                14   14 (2)   0
  5\) Amerchol L101                                                       47                       23 (11)                             23                              11 (10--15)   36 (4)   5\) Wollwachsalkoholsalbe DAB9[c](#jdv14973-note-0005){ref-type="fn"}   30   27 (8)    27   3--12) Wollwachsalkoholsalbe DAB9[c](#jdv14973-note-0005){ref-type="fn"}   14   14 (2)   14
  6\) Wollwachsalkoholsalbe DAB9[c](#jdv14973-note-0005){ref-type="fn"}   44                       23 (10)                             23                              11 (9--17)    20 (2)   6\) Cocamidopropyl betaine                                              28   25 (7)    25   3--12) Fragrance mix I                                                     14   14 (2)   14
  7\) Cremor lanette[d](#jdv14973-note-0006){ref-type="fn"}               40                       18 (7)                              18                              15 (10--15)   29 (2)   7\) Cremor lanette[d](#jdv14973-note-0006){ref-type="fn"}               29   24 (7)    24   3--12) 2‐n‐octyl‐4‐isothiazolin‐3‐one                                      14   14 (2)   14
  8\) Dimethylaminopropylamine                                            42                       17 (7)                              17                              12 (11--21)   29 (2)   8\) Dimethylaminopropylamine                                            28   18 (5)    18   3--12) Iodopropynyl butylcarbamate                                         14   14 (2)   14
  9\) Cobalt(II)‐chloride                                                 44                       11 (5)                              3                               11 (10--17)   60 (3)   9\) Eucerine cum aqua[e](#jdv14973-note-0007){ref-type="fn"}            30   13 (4)    0    3--12) Sorbitansesquioleate                                                14   14 (2)   0
  10\) Eucerine cum aqua[e](#jdv14973-note-0007){ref-type="fn"}           40                       10 (4)                              10                              11 (10--14)   0 (0)    10\) Cobalt(II)‐chloride                                                29   14 (4)    14   3--12) Benzophenone 4                                                      14   14 (2)   14
  Add 1. Fragrance mix I                                                  44                       9 (4)                               9                               24 (6--51)    50 (2)   Add 1. Unguentum lanette                                                28   7 (2)     7    3--12) Sodium metabisulfite                                                14   14 (2)   7
  Add 2. Unguentum lanette                                                40                       8 (3)                               8                               11 (10--13)   33 (1)                                                                                               3--12) DimethylaminopropylamineAdd 1. Wool alcohols                        14   14 (2)   14

RPTT: relevant positive patch test: to obtain a rate for allergens that were both the most common and the most relevant, we multiplied the prevalence (PPT%) with the relevance score of 'definite' and 'probable', current relevance, obtaining the percentage of clinically relevant patch tests (RPPT%).

Caine‐mix III: Benzocaine, Dibucaine‐HCI (cinchocaine), and Tetracaine‐HCI (amethocaine).

Wollwachsalkoholsalbe DAB9: German wool wax emollient (75% wool wax and 25% water).

Cremor lanette: 10% cetostearyl alcohol, 1% sodiumlaurylsulphate, 14% cetiol V, 3% sorbitol 70%, 0.1% sorbic acid, 72% H~2~O.

Eucerine cum aqua: 56% white petrolatum, 3.5% wool alcohols, 0.5% cetylstearyl alcohol, 40% H~2~O.

Add, additional allergens represent allergens that would rank in the top 10 according to RPTT%; PPT, positive patch test; UK+, atopic dermatitis meeting UK Working Party criteria.
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The RPPT% shows that fragrance mix I (*n* = 4/44, PPT 9%, RPPT 9%) and unguentum lanette (*n* = 3/40, PPT 8%, RPPT 8%) are allergens that when positive, are more important in explaining clinical findings than nickel and cobalt, which in RPTT% rank 17th and 21st, respectively. This shows that although nickel and cobalt are common allergens, they are seldom considered to be of current relevance in this AD population.

Dynamic pattern analysis {#jdv14973-sec-0014}
------------------------

Results of dynamic pattern analysis can be found in Table [4](#jdv14973-tbl-0004){ref-type="table"}. Bichromate and fragrance mix I are the only allergens in which allergic reactions also occurred as being decrescendo. This means that only in bichromate and fragrance mix I, positive patch tests can indicate irritative reactions instead of truly allergic reactions. All other allergens display plateau and crescendo patterns, indicating true allergic reactions.

###### 

Dynamic pattern analysis of the 10 most common and relevant allergens (highest RPTT%) in 48 UK+ difficult‐to‐treat atopic dermatitis patients

                                                         Total   Crescendo   Plateau   Decrescendo
  ------------------------------------------------------ ------- ----------- --------- -------------
  Wool alcohols                                          10      100 (10)    0 (0)     0 (0)
  Cocamidopropyl betaine                                 10      90 (9)      10 (1)    0 (0)
  Amerchol L101[a](#jdv14973-note-0009){ref-type="fn"}   15      87 (13)     13 (2)    0 (0)
  Wollwachsalkoholsalbe                                  10      80 (8)      20 (2)    0 (0)
  Cremor lanette                                         7       86 (6)      14 (1)    0 (0)
  Dimethylaminopropylamine                               7       71 (5)      29 (2)    0 (0)
  Bichromate[b](#jdv14973-note-0010){ref-type="fn"}      11      9 (1)       55 (6)    36 (4)
  Eucerine cum aqua                                      4       75 (3)      25 (1)    0 (0)
  Unguentum lanette                                      3       67 (2)      33 (1)    0 (0)
  Fragrance mix I                                        4       50 (2)      25 (1)    25 (1)

Amerchol L101 was present in the wool alcohol series and in routine supplementary series; therefore, some patients were tested more than once.

In one patient with a positive test, patch test reading was performed only on day 2; this patient could therefore not be included in dynamic patch testing.

UK+; meeting UK Working Party criteria.

Dynamic pattern analysis was carried out amongst all patients with readings on D2 and D3, with a positive reading on either of these days, non‐follicular and non‐irritative; therefore, the *n* does not represent all patients tested, but only positive readings.
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Additionally, in wool alcohols, amerchol L101 and fragrance mix I (data not shown), a doubtful positive reaction was seen on D2; however, all these reactions developed to a '+' reaction. In contrast, in cremor lanette, DMAPA and eucerine cum aqua all doubtful positive D2 reactions disappeared at the later reading.

Polysensitization {#jdv14973-sec-0015}
-----------------

Polysensitization was present in 39% (*n* = 14/36) of sensitized patients. There was no difference in the age of patients monosensitized (median age 16.3 years; IQR: 10.9--21.4) or polysensitized (median age 13.9; IQR: 10.1--24.9; *P* = 0.51).

Polysensitization occurred to three or four groups of allergens (both *n* = 5, 36%), as well as to five or more allergen groups (*n* = 4, 29%). In polysensitized patients, the most common allergen groups to which sensitization occurred were wool alcohols (*n* = 10/14, PPT 71%), followed by metals and preservatives (both *n* = 9/14, PPT 63%; Table [5](#jdv14973-tbl-0005){ref-type="table"}). Within polysensitized patients, of the wool alcohol group, amerchol L101 was the allergen that was positive most often (*n* = 7/13, PPT 54%), within metals these were nickel (*n* = 5/13, PPT 36%) and bichromate (*n* = 5/14, PPT 36%) and within preservatives benzophenone‐4 (*n* = 4/14, PPT 29%; data not shown).

###### 

Sensitization prevalences of allergen groups[a](#jdv14973-note-0013){ref-type="fn"} within 14 polysensitized UK Working Party criteria difficult‐to‐treat AD patients

  Allergen group[a](#jdv14973-note-0013){ref-type="fn"}   *n* (%)
  ------------------------------------------------------- ---------
  Wool alcohols                                           10 (71)
  Metals                                                  9 (64)
  Preservatives                                           9 (64)
  Surfactants                                             6 (43)
  Fragrances                                              6 (43)
  Rubbers                                                 4 (29)
  Local anaesthetics                                      3 (21)
  Corticosteroids and DMSO                                3 (21)
  Sorbitan sesquioleate                                   2 (14)
  p‐phenylenediamine (PPD) and PPD‐like agents            2 (14)
  Epoxy resins                                            1 (7)
  Formaldehyde and formaldehyde releasers                 1 (7)
  Antioxidants                                            0 (0)
  Antibiotics                                             0 (0)
  Clioquinol                                              0 (0)
  Composites                                              0 (0)
  Ethylenediamine                                         0 (0)
  p‐tert‐butylphenol                                      0 (0)
  Primin                                                  0 (0)

Grouping of allergens is based on cross‐reactivity, concomitant exposure and releasers of similar compounds.
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Discussion {#jdv14973-sec-0016}
==========

This study shows that ACD and polysensitization are frequent within difficult‐to‐treat AD patients. The group composition of the population under study is dominated by children, with only a quarter of patients having reached adult age. A recent large study conducted in three University Hospitals in The Netherlands, including our centre, showed that 48% of children with AD who were tested based on clinical suspicion had one or more positive patch test reactions compared to 47% of children without AD.[21](#jdv14973-bib-0021){ref-type="ref"} In the current study, we found a sensitization rate of 71% (*n* = 24/34) in children and 86% (*n* = 12/14) in adults amongst 48 difficult‐to‐treat AD patients. This prevalence in children is much higher than in the previously mentioned study by Lubbes *et al*.[21](#jdv14973-bib-0021){ref-type="ref"} and exceeds the prevalence of 30% in AD children and adolescents reported by Simonsen *et al*.[34](#jdv14973-bib-0034){ref-type="ref"} Our findings reflect the higher prevalence of ACD in this selected difficult‐to‐treat AD patient group as compared to patients with AD patch tested due to clinical suspicion during routine outpatient care or to screen for contact allergies. The mean EASI of 25 shows that this is indeed a group of severe AD patients,[35](#jdv14973-bib-0035){ref-type="ref"} which makes it a different subgroup compared to mild AD patients, with therefore different rates of contact sensitization.

It has been shown that in a general population patch tested because of ACD suspicion, one of every six to seven ACD patients (14--16%) had multiple allergies.[36](#jdv14973-bib-0036){ref-type="ref"} The amount of polysensitization we found exceeded this number. However, AD is a known risk factor for polysensitization, and polysensitized patients with AD have been shown to have a more persistent dermatitis,[32](#jdv14973-bib-0032){ref-type="ref"} which may explain the high number of polysensitization in our population. More interestingly, also wool alcohol allergy has been associated with polysensitization.[37](#jdv14973-bib-0037){ref-type="ref"} Although it seems intuitive that severe AD patients having severe impaired skin barrier would have more penetration of allergens and therefore an increased prevalence of ACD, this is a topic of ongoing discussion.[38](#jdv14973-bib-0038){ref-type="ref"} As permeability to hydrophilic solutes may increase through imperfection in lipid layers[39](#jdv14973-bib-0039){ref-type="ref"} and in AD stratum corneum lipid organization is affected,[40](#jdv14973-bib-0040){ref-type="ref"} this may increase permeability of hydrophilic zwitterionic surfactants such as CAPB and DMAPA. Additionally, other surfactants, such as present in wool alcohols, may also increase penetration of other compounds.[41](#jdv14973-bib-0041){ref-type="ref"} Also, the influence of emollients on the skin microbiome[42](#jdv14973-bib-0042){ref-type="ref"}, [43](#jdv14973-bib-0043){ref-type="ref"} could change the tolerance against several allergens[44](#jdv14973-bib-0044){ref-type="ref"} making frequent emollient applicators more prone to ACD. For this subject, however, more detailed research is warranted.

Experimental settings show an inverse relationship between AD and ACD, hypothetically because of antagonistic influences of Th1 (ACD) and Th2 (AD). More recent research, however, indicates that ACD cannot be a single entity, and the murine model of sensitization does not self‐evidently apply to the human situation. For example, wherein the murine model ACD was induced by a potent sensitizer, dinitrofluorobenzene, human ACD can also be elicited by less potent sensitizers, such as nickel, which do not induce ACD in mice.[45](#jdv14973-bib-0045){ref-type="ref"}

Most positive reactions were seen against metals, wool alcohols and surfactants, but when taking relevance into account, the 10 most frequent allergens are made up by wool alcohols, surfactants (CAPB and DMAPA), bichromate and fragrance mix I. There is much debate about whether positive patch test reactions to wool alcohols and CAPB/DMAPA are truly allergic or mainly irritative in patients with AD.[46](#jdv14973-bib-0046){ref-type="ref"} For this reason, we performed dynamic pattern analysis, which shows that reactions to wool alcohols and CAPB/DMAPA have an allergic rather than an irritant pattern, indicating true allergic reactions.

Sensitization to wool alcohols in this population was quite frequent. In previous studies, where only a selected group of wool alcohol derivatives have been tested, lower numbers of wool alcohol sensitization were found.[14](#jdv14973-bib-0014){ref-type="ref"}, [17](#jdv14973-bib-0017){ref-type="ref"}, [20](#jdv14973-bib-0020){ref-type="ref"}, [26](#jdv14973-bib-0026){ref-type="ref"} However, also prevalences of 24% wool alcohol sensitization have been reported previously.[47](#jdv14973-bib-0047){ref-type="ref"} In our study, patients were tested with a wool alcohol series, which may lead to a better detection of wool alcohol allergies. The high number of wool alcohol sensitization found in our population may also be inherent to the studied population of difficult‐to‐treat AD itself. One of the reasons why this population may be 'difficult‐to‐treat' may in fact be the direct result from their concomitant contact allergy to wool alcohols, which are frequently present in emollients as well as in therapeutic ointments prescribed by dermatologists. The very medication intended to treat the AD may actually be eliciting an ACD, clinically mimicking an AD flare. If gone unrecognized, this may result in a vicious circle of increased use of topical treatments eliciting more dermatitis, ultimately resulting in a case of difficult‐to‐treat 'AD'. Important to note is that of the 48 patients excluded from further analyses because of not meeting UK Working Party criteria, the nine patients (*n* = 9/48) who were patch tested, all had a contact allergy. These patients were all clinically diagnosed with AD but did not meet the diagnostic criteria for AD retrospectively. One could speculate that these patients may have been clinically misdiagnosed as AD, and actually had an ACD instead, but this was not further investigated.

Another interesting finding is the high prevalence and relevance of reactions to surfactants CAPB/DMAPA. As the presence of these surfactants is frequent in daily cosmetic products (shampoo, liquid soap, toothpaste), sensitization to the agents could easily occur. High prevalences of CAPB/DMAPA contact allergies have been found by other authors as well, but are underreported as they are often not tested, as they are not in the EBS and only tested on indication.[25](#jdv14973-bib-0025){ref-type="ref"}, [48](#jdv14973-bib-0048){ref-type="ref"}, [49](#jdv14973-bib-0049){ref-type="ref"} The allergenic potential of CAPB has been disputed, and it is argued whether CAPD is a true allergen or only an irritant.[50](#jdv14973-bib-0050){ref-type="ref"} As CAPB and DMAPA only show crescendo and plateau patterns in our dynamic pattern analysis, we think that at least in this population they reflected true allergic reactions.

As we studied an AD population with recalcitrant disease, we had expected more allergic reactions to corticosteroids. Especially, group A corticosteroid allergy has been associated with AD.[51](#jdv14973-bib-0051){ref-type="ref"} Probably, in recalcitrant AD disease, exposure to group A corticosteroids is lower and group B--D corticosteroids are prescribed more often. However, we did not find these reactions in our study population.

Based on our results, we would advise to have a high level of suspicion and readily patch test patients with difficult‐to‐treat AD as part of their diagnostic workup. A frequent problem encountered by dermatologists treating these patients is that patch testing cannot be performed due to the active dermatitis, and therefore, contact allergies will not be detected in this group. However, in our experience, by putting the patients on a strict regimen of usage of only toiletries and topical treatments free of wool alcohols, CAPB/DMAPA and fragrances, combined with adequate topical anti‐inflammatory treatment, frequent use of emollients and regular use of bleach baths, these patients can usually be tested within 6--12 weeks. This usually is easier to achieve in children, as they do not yet need as many toiletries as adults.

The main limitations of this study are its retrospective nature and its relative small sample size. Not all patients with difficult‐to‐treat AD were tested systematically, as testing was performed only based on clinical suspicion. EASI scores were not available in all patients. Other less frequently tested relevant allergens were not studied. Other causes for why the AD was difficult‐to‐treat, for instance possible lack of functional filaggrin, were not explored in this study.

In conclusion, we found high rates of concomitant ACD and polysensitization in a population of difficult‐to‐treat AD children and adults. The most frequent and relevant reactions were seen against wool alcohols, surfactants such as CAPB and DMAPA, bichromate and fragrance mix 1. Dynamic pattern analysis indicates that these reactions were allergic and not irritative of nature. Based on these results, avoidance of contact with these allergens seems to be advisable for patients with difficult‐to‐treat AD. More research into wool alcohol ACD within patients with AD is warranted, as current prescription habits seem effective,[52](#jdv14973-bib-0052){ref-type="ref"} although their role in the development of difficult‐to‐treat AD and polysensitization is unclear for the AD population in general.
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